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a  b  s  t  r  a  c  t
Tuberous  sclerosis  complex  (TSC)  results  from  mutation  of TSC1  or TSC2  that  encode  for  hamartin  and
tuberin.  It affects  the kidneys  often  in advance  of  extra-renal  stigmata.  We  studied  14  TSC  cases,  and  4
possible  TSC  cases  with  multiple  angiomyolipomas  (AMLs)  for hamartin  and  tuberin  protein  expression
to  determine  if the  staining  proﬁle  could  predict  mutation  status  or likelihood  of  TSC with  renal-limited
disease.  The  18  cases  included  15  nephrectomies  and  1 section  of  6 TSC-associated  renal  cell  carcinomas
(RCC).  Controls  included  the  non-neoplastic  kidney  in  5  tumor  nephrectomies,  4 sporadic  cases  of AML
and  6 clear  cell  RCCs.  In the  14  TSC  cases,  9 had AMLs,  9 had  RCCs,  5 had  polycystic  kidney  disease
and  8  had  eosinophilic  cysts  (EC)  lined  by  large  eosinophilic  cells.  The  controls  and  study  cases  showed
luminal  staining  of  proximal  tubules  (PT)  and  peripheral  membrane  staining  in  distal  tubules/collecting
ducts  for  hamartin  and  cytoplasmic  staining  for tuberin.  Eosinophilic  cysts  had  a luminal  PT-like  stain
with  hamartin  and  a cytoplasmic  reaction  for tuberin.  Hamartin  stained  myoid  cells  in all  AMLs.  Tuberin
was  negative  in  all but 1AML, an  epithelioid  AML.  All  but  1 RCC  were positive  for  tuberin;  13 RCCs  (7
TSC/6  non-TSC)  were  negative  for  hamartin  and  4 showed  a weak  reaction.  We  conclude  that  the  ECs  of
TSC  are  proximal  tubule-derived.  The  hamartin  and  tuberin  staining  proﬁles  of  AMLs  and  most  RCCs  are
reciprocal  precluding  prediction  of the  mutation  in TSC,  and  fail  to predict  if a patient with multifocal
AML  has  TSC.
ors.  P©  2016  The  Auth
. IntroductionTuberous sclerosis complex (TSC) is an autosomal dominant dis-
rder that affects 1 in 6000 people [1,2]. It results from mutation
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of 1of 2 genes, TSC1 or TSC2, that encode for hamartin and tuberin,
respectively, and has 95% penetrance but highly variable clinical
expression and severity [1–4]. TSC1 is less common than TSC2
accounting for 29% of cases, while TSC2 is associated with a more
severe clinical phenotype [2].
Tuberous sclerosis complex is characterized by neoplasms and
cysts that affect multiple organs [1,2]. Renal involvement occurs in
60–80% and is clinically signiﬁcant in 45%. It consists of angiomy-
olipomas (AML), cysts and polycystic kidney disease (PKD), and
rarely, renal cell carcinoma (RCC) and oncocytoma [5–12]. The
renal lesions may  occur singly or in combination, are often multi-
focal and bilateral, and may  precede other stigmata of TSC [1,2,5,6].
The diagnosis of TSC can be challenging since the proﬁle of organ
le under the CC BY license (http://creativecommons.org/licenses/by/4.0/).




















































Tuberous sclerosis-related pathology ﬁndings.
Case Age/sex Cysts Angiomyolipoma RCC
PKD EC EMC  Macro Micro AMLEC AMLosis
Group1
1 1w/F + + +
2  38y/F + + + + + +
3  58y/F + + + +
4 21y/F + + + +
5  30y/F + + +
6  23y/F + + + + + A × 2
7  36y/F + + + + + + + A − M/B
8  11y/F + + + + + A × 2
9  24y/F n/a n/a n/a n/a + A
10  38y/M n/a n/a n/a n/a + B
11  52y/M n/a n/a n/a + + B
12  25y/F n/a n/a n/a n/a + C
13  42y/F n/a n/a + + + C
14  58y/F n/a n/a n/a n/a + C
Group 2
15 35y/F + +
16 60y/F + +
17 64y/M + +
18 69y/F + + +
Total 5 5 9 12 9 4 2 9
AML—Angiomyolipoma; Macro—Macroscopic; Micro—Microscopic;
AMLEC—Angiomyolipoma with epithelial cyst; AMLosis—Angiomyolipomatosis;
PKD—Polycystic kidney disease; EC—Eosinophilic cyst; EMC—Eosinophilic micro-
cyst; RCC—Renal cell carcinoma; A—Eosinophilic-microcystic RCC; B—RenalS.M. Bonsib et al. / Pathology – Res
nvolvement is diverse, and 65% of cases represent a new mutation
o a positive family history is often lacking [1,2].
The clinical criteria for a diagnosis of TSC have evolved over the
ast few decades. Gomez in 1991 proposed a hierarchy of clini-
al and imaging features clustered into three categories; deﬁnitive,
resumptive and suspect [13]. With the Gomez Criteria, the pres-
nce of multiple AMLs in a single kidney was regarded as deﬁnitive
f TSC. The diagnostic criteria were made more stringent in 1998
nd updated in the 2012 International Tuberous Sclerosis Com-
lex Consensus Conference [14]. A deﬁnitive diagnosis of TSC now
equires 2 different major lesions, or 1 major and 2 minor lesions,
ather than multiple lesions of the same type [14]. Even with 2
ajor features to support a clinical diagnosis of TSC, genetic testing
ill only identify a mutation in 85% of patients [2].
Since renal involvement may  precede other stigmata of TSC and
arents with only AMLs may  have children severely affected by TSC,
iagnostic quandaries arise when multifocal renal AMLs are iden-
iﬁed [15]. This study evaluates the immunohistochemical staining
roﬁles for hamartin and tuberin in TSC to determine their utility as
 surrogate marker for the underlying genetic mutation, especially
elevant in the cases of possible TSC where multifocal renal AMLs
re present as the sole clinical ﬁnding.
. Material and methods
Eighteen cases of TSC (14 cases) or possible TSC (4 cases) were
tudied. The TSC cases fulﬁlled criteria of the 2012 International
uberous Sclerosis Complex Consensus Conference [14]. The possi-
le TSC cases contained multifocal AMLs which satisﬁed the 1991
omez criteria for TSC [13]. The cases were obtained from multi-
le institutions; Indiana University, Indianapolis, IN, The University
f Arkansas for Medical Sciences, Little Rock, AR, Louisiana State
niversity, Shreveport, LA, Mayo Clinic, Rochester, MN,  Cleveland
linic, Cleveland, OH, William Beaumont Hospital, Royal Oak, MI,  El
amino Hospital, Mountain View, CA, Stanford University, Stanford,
A, and Lille University Hospitals, Lille, France.
Immunoperoxidase stains for hamartin, C-2 monoclonal IgG2
apping to N-terminus of hamartin of human origin (1:100 dilu-
ion) and tuberin, N-19 rabbit polyclonal IgG mapping to the
-terminus of tuberin of human origin (1:100 dilution), Santa
ruz Biotechnology, were performed. The materials available for
eview consisted of 15 nephrectomies or partial nephrectomies
rom twelve cases (3 were bilateral) and a single section of a RCC in
 cases, for a total of 21 specimens. The non-neoplastic kidney from
 nephrectomies performed for renal cell carcinoma, 4 cases of spo-
adic AML and 6 cases of sporadic clear cell RCC in patients served as
mmunoperoxidase stain controls. Demographic and clinical infor-
ation was available on all cases. This study is IRB approved.
Immunoperoxidase staining was semi-quantitatively scored as
–3+ as follows:
0—no staining
1+—staining clearly above the background negative cells involv-
ng fewer than 25% of the cells of interest
2+—prominent staining of a large fraction of the cells, 25–50%,
r all of the cells of interest, but less than the strongest positive
ontrols
3+—diffuse staining in >50% of the cells of interest, equal to the
trongest positive controls
. DeﬁnitionsFor purposes of this study the following deﬁnitions were
mployed.
Cyst—an epithelial lined structure grossly visible in a nephrec-
omy specimen or on a glass slide.angioadenomyomatous tumor; C—Chromophobe cell RCC.
n/a—Not applicable because one section was  reviewed for this study.
Eosinophilic microcyst—an ectatic tubule not grossly visible in
a nephrectomy specimen or on a glass slide, lined by eosinophilic
cells with prominent nucleus and having larger cytoplasmic volume
and luminal diameter than the adjacent normal proximal tubules.
Eosinophilic cyst—an epithelial-lined structure grossly visible in
a nephrectomy specimen or on a glass slide lined by enlarged
eosinophilic cells similar to the eosinophilic microcysts.
Polycystic kidney disease—a kidney diffusely transformed by
cysts. Its overall size may  be smaller or larger than normal.
Angiomyolipoma, macroscopic—a grossly visible angiomy-
olipoma. It may  be a classic tri-phasic tumor containing lipid-rich
cells, myoid cells and abnormal arteries, or may  be lipid-rich cell
or myoid cell predominant.
Angiomyolipoma with an epithelial-lined cyst (AMLEC)—an
angiomyolipoma variant consisting of a myoid predominant AML
that contains an epithelial-lined cyst surrounded by a cellular “cam-
bium” layer interposed between the myoid cells and the cyst [16].
Angiomyolipoma, microscopic—a small, circumscribed, mm-
sized or less AML, not grossly visible, usually lipid-rich or myoid
cell predominant, often referred to in the literature as a “micro-
hamartoma”.
Angiomyolipomatosis—an ill-deﬁned uncircumscribed intersti-
tial proliferation of angiomyolipomatous tissue consisting of myoid
cells, lipid-rich cells, or both, present as individual cells or forming
cords of cells. Abnormal arteries are not present.
4. Results
4.1. Deﬁnition of groups
Twenty-one specimens from 18 patients were reviewed. The
ﬁndings were similar for each side in patients in which both kid-
neys were examined so the results will be presented as number
of patients rather than number of specimens examined. The cases
were divided into two  groups (Table 1). Group 1 consists of 14 TSC
cases that satisﬁed the criteria of the 2012 International Tuberous
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Fig. 1. (A) Microscopic angiomyolipoma. This shows a microscopic myoid cell




























Fig. 2. (A) Eosinophilic cysts. These are eosinophilic cysts lined by plump focally
stratiﬁed eosinophilic cells. (B) Polycystic Kidney. This bilateral nephrectomy in a
TSC  patient shows polycystic kidney disease and multiple and bilateral angiomy-
olipomas. Angiomyolipomatosis, although not grossly apparent, diffusely replaced
the parenchyma. Note the marked reduction in kidney size despite the presence ofpicuous, interstitial cords and individual lipid-rich and myoid cells that course
hroughout the renal parenchyma.
clerosis Complex Consensus Conference [14]. Group 2 consisted
f 4 possible TSC cases that had multifocal AMLs but no extrarenal
tigmata of TSC that satisﬁed the 1991 Gomez criteria for TSC [13].
.2. Group 1
Group 1 consisted of 2 children and 12 adults. The ages of
he 2 children were 1week and 11years. The ages of the adults
anged from 21 to 58 years with an average of 37 years. In 12
ephrectomies multifocal AMLs were present in 9 cases that ranged
rom macroscopic tumors (7 cases) to microscopic AML  (6 cases)
Fig. 1A). The composition of the AMLs varied from predominately
ipid-rich cells, to predominately myoid cells, to triphasic. Two
ases demonstrated AMLosis, characterized by ill-deﬁned prolif-
rations of myoid cells and lipid-rich cells that insinuated between
ormal or atrophic nephron elements (Fig. 1B). Three patients had
MLECS.
Renal cell carcinomas were present in 9 patients (Table 1). Six
ases were previously reported in detail by 3 authors (AS, XL and
M)  [17]. The histology of the RCCs varied; 3 “types” of RCCs were
dentiﬁed. Two RCCs resembled the so-called renal angiomyoade-
omatous tumor (RAT), a tumor characterized by nests of large
ells with clear cytoplasm traversed by bundles of smooth muscle.
hree RCCs resembled sporadic cases of chromophobe cell RCC. Five
CCs were composed of large eosinophilic focally vacuolated cells
ith large vesicular nuclei that exhibited architectural variability,
ccasionally solid, but often cystic. One patient had multiple and
ilateral macroscopic RCCs and numerous microscopic RCCs and 2
atients had 2 small RCCs (3 mm to 1 cm). These eosinophilic-cysticcysts and tumors.
RCCs would qualify as RCC, unclassiﬁed by the 2004 WHO  and the
2013 ISUP classiﬁcations [18,19].
Eosinophilic cysts (EC) and eosinophilic microcysts (EMC) were
present in 5 and 8 patients, respectively, associated with cysts hav-
ing ﬂattened to low cuboidal epithelium. The ECs and EMCs were
lined by large cells with dense eosinophilic, occasionally vacuolated
cytoplasm and vesicular nuclei (Fig. 2A). Although a single layer of
eosinophilic cells was  most common, occasionally cell stratiﬁcation
was present. Five patients had numerous bilateral cysts consistent
with PKD (Fig. 2B). The cysts included both ECs and EMCs, and cysts
lined by ﬂattered or cuboidal epithelium. Six of 8 cases with ECs
and/or EMCs had macroscopic AMLs and 3 of 8 also had RCCs.
4.3. Group 2
Group 2 consisted of 4 patients with multifocal, or multifocal
and bilateral AMLs. Their average age was 57 years, 20 years older
than cases in Group 1 (Table 1). Two  patients with the largest
AMLs, both 9 cm,  presented with perinephric hemorrhage. The
AMLs ranged from macroscopic to microscopic (Fig. 3). One case
also contained 2 AMLECs. AMLosis was  not present, and by deﬁni-
tion, PKD, EC and EMC  were not present.












































Fig. 4. (A) Control kidney. This control kidney stained for hamartin show a brush
border reaction in proximal tubules and peripheral cell membrane reaction in col-
lecting ducts on the left. Glomerular cells are also positive. Immunoperoxidase stain
Five patients had both RCCs and AMLs that, in general, showedig. 3. Multiple angiomyolipomas. This kidney contained multiple lipid-rich cell
redominant angiomyolipomas.
.4. Hamartin and Tuberin Immunohistochemistry
Immunohistochemical stains for hamartin and tuberin were
erformed on 5 control nephrectomies, 4 sporadic AMLs (single
umor), 6CC-RCCs and on 1–3 blocks from cases in Group 1 and
roup 2. The cases were examined for hamartin and tuberin stain-
ng of the various normal nephron components, and the cysts,
icrocysts and neoplasms, if present.
Control nephrectomies showed hamartin and tuberin stain-
ng in all nephron structures, glomeruli, proximal tubules (PT)
nd distal tubules (DT), and in collecting ducts (CD) (Fig. 4A and
). The glomerular staining was weak (1+), possibly because the
ytoplasmic volume of glomerular cells is much less than tubular
ells. Parietal epithelial cells, podocytes, mesangium cells, endothe-
ial cells stained positive in glomeruli of all cases. The vascular
ndothelium of arterioles and arteries, and the smooth muscle
ells of arterioles, arteries, veins and collecting system muscu-
aris were also positive. The pattern of tubular staining differed
etween hamartin and tuberin. Hamartin demonstrated a 2–3+
istinct brush border-like luminal staining of PT and a peripheral
ell membrane pattern in DT and CD with weak cytoplasmic stain-
ng (Fig. 4A). Conversely, tuberin showed a 3+ diffuse cytoplasmic
eaction in all tubular segments (Fig. 4B).
The normal nephrons of 11 cases from Group 1 and 4 cases of
roup 2 showed an identical staining pattern for hamartin and
uberin as the controls. Three RCCs from Group 1 lacked an inter-
al control of normal kidney for evaluation. The ECs and EMCs of
roup 1 stained for both hamartin and tuberin (Table 2) (Fig. 5A–C).
he hamartin stain pattern was apical in most ECs and in all EMCs,
imilar to the staining of control proximal tubules. Tuberin showed
 diffuse cytoplasmic reaction. Cysts with a ﬂat atrophic epithelial
ining were usually negative for both hamartin and tuberin.
Hamartin stained all 22 macroscopic AMLs and all microscopic
MLs in which myoid cells were present (Table 2) (Fig. 6A). The
taining pattern ranged from 3+ diffuse and strong, to 2+ mod-
rate focal staining similar to the focal staining with HMB-45
haracteristically observed in AMLs. The lipid-rich cells of AMLs
ppeared negative, therefore, lipid-rich cell predominant AMLs
ere largely or completely negative. The 2 cases with intersti-
ial AMLosis showed extensive interstitial hamartin positive myoid
ells. All 4 of the AMLECs showed 2–3+ hamartin staining of the
yst epithelium, the cambium layer cells and the AML  myoid cells.
amartin did not show a luminal or peripheral cell membrane pat-
ern of normal PT or DT/CD, respectively. Hamartin also stained
–3+ the multifocal AMLs of Group 2 that contained myoid cells
nd the 4 sporadic cases of AML.for hamartin. (B) Control kidney. This control kidney stained for tuberin show dif-
fuse cytoplasmic reaction in proximal tubules and distal tubules. Glomerular cells
are  also positive. Immunoperoxidase stain for tuberin.
Tuberin staining was completely negative in 21 of 22 macro-
scopic AMLs, all microscopic AMLs and in AMLosis (Fig. 6B). The
one macroscopic AML  positive (3+) for tuberin was  an epithelioid
AML, the only one in this study. All 4 of the AMLECS showed 2–3+
tuberin staining of the cyst epithelium while the cambium layer
cells and myoid cells stained in 1 of 4 cases. None of the multifocal
AMLs of Group 2 or the 4 sporadic cases of AML showed tuberin
staining.
Nine TSC cases with 11 RCCs of the three types were studied
for hamartin and tuberin. All 11 RCCs demonstrated a diffuse 2–3+
reaction for tuberin (Table 2) (Fig. 7A). Their supporting microvas-
culature, however, was  negative for tuberin. The smooth muscle
within the 2 RAT tumors was  tuberin negative. Tuberin was also
positive (1–2+) in 5 of 6 control CC-RCC.
Seven RCCs were negative for hamartin (Fig. 7B). Four
RCCs (2/3Chromophobe, 1/2 RAT, 1/4 eosinophilic-microcystic),
however, showed a 1+ reaction for hamartin. The supporting
microvasculature in all RCCs stained strongly for hamartin, and the
smooth muscle within the 2 RAT tumors was also strongly posi-
tive (3+). The 6CC-RCCs were negative for hamartin. However, their
supporting microvasculature was positive.a reciprocal tumor staining for hamartin and tuberin (Fig. 8A–C).
Three patients showed positive hamartin/negative tuberin in their
AMLs, with negative hamartin/positive tuberin in their RCCs. The 2
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Table 2
Hamartin and Tuberin Immunohistochemistry.
Tuberous Sclerosis Hamartin Positive (Intensity) Tuberin Positive (Intensity)
Eosinophilic cysts and microcysts (# cases) 8 of 8 7 of 7
Angiomyolipomas (# tumors) 22 of 22 (2–3+) 1a of 22 (3+)
AMLECs (# tumors)
Epithelium 4 of 4 4 of 4
Cambium, Smooth muscle 4 of 4 1 of 4
Renal cell carcinomas (# tumors)
Eosinophilic-microcystic RCC 1 of 4 (1+) 4 of 4 (2–3+)
Renal  angioadenomyomatous tumor
Epithelial cells 1 of 2 (1+) 2 of 2 (2+)
Smooth muscle stroma 2 of 2 (3+) 0 of 2
Chromophobe RCC 2 of 3 (1+) 3 of 3 (2–3+)
Total  RCCs 4 of 9 (1+) 9 of 9 (2–3+)
Possible Tuberous Sclerosis (# cases)
Multifocal AML  4 of 4 (2–3+) 0 of 4
Non-tuberous Sclerosis(# cases)
Single AML  4 of 4 (2+) 0 of 4







































sMLEC—angiomyolipoma with epithelial cysts; RCC—renal cell carcinoma.
a Epithelioid AML.
ther patients also showed positive hamartin/negative tuberin in
heir AMLs, but had weak (1+) positive hamartin/positive tuberin
n their RCCs.
. Discussion
Tuberous sclerosis complex is a disorder of cellular migration,
roliferation and differentiation leading to cysts and neoplasms
hat affect multiple organs, most commonly skin, central nervous
ystem and kidney [1,2]. Tuberous sclerosis complex results from
 mutation of TSC1 or TSC2, that encode for hamartin and tuberin,
espectively [3,4]. More than 300 allelic variants of TSC1 and more
han 1000 allelic variants of TSC2 have been described. Approxi-
ately 65% of TSC represent a de-novo mutation, so family history
s often lacking [1–5]. Mutations involving TSC1 tend to be small
eletions or insertions and nonsense mutations, while TSC2 may
ave large deletions or rearrangements [20]. Approximately 2% of
SC2 patients have large mutations affecting both TSC2 and PKD1,
n adjacent gene on chromosome 16, resulting in the TSC12/PKD1
ontiguous gene syndrome (CGS) and early onset PKD, often prior
o other stigmata of TSC [8,10–12]. The lesions of TSC are believed to
ollow the classic “Knudson model” where a single allelic germline
utation of TSC1 or TSC2 is coupled with a somatic mutation to the
ther allele leading to loss of function [1,2].
The products of TSC1 and TSC2, hamartin and tuberin, are mul-
ifunctional proteins that form a cooperative complex [21–25]. The
linical similarity between patients with TSC1 or TSC2 mutations
upports the notion that mutations in either gene affect the func-
ion of the TSC protein complex. In normal cells, the TSC complex
egatively regulates mammalian target of rapamycin (mTOR), a
omponent of the PI3K/AKT/mTOR pathway, through inhibition of
TP-binding protein Rheb (Ras homolog enriched in brain) [21–25].
oss of the TSC complex leads to unrestrained Rheb activation of
TORC1, a complex containing mTOR, to stimulate downstream
athways involved in cell growth and proliferation via phosphory-
ation of ribosomal protein S6 kinase beta1 and eukaryotic initiation
actor 4E-binding protein-1. Evidence also suggests that hamartin
nd tuberin have individual, non-TSC complex related activities
24,25].Renal AMLs are the most common renal abnormality in TSC.
ike their sporadic counterparts, they show considerable histo-
ogic variation with lipid-rich cell or myoid cell predominance,
how an epithelioid or oncocytoma-like phenotype and maycontain an epithelial cyst (AMLEC). We  describe herein an inter-
stitial AML  proliferation, referred to as angiomyolipomatosis,
composed of individual cells or slender cords of cells that inﬁltrate
around nephron elements. It lacks the circumscription of micro-
scopic AMLs, and may  replace the majority of the renal parenchyma
without producing a grossly visible lesion.
The presence of multiple AMLs has historically raised concern
of a forme fruste of TSC (Gomez criteria) when a family history is
lacking since a parent with a single AML  may  have a child severely
affected by TSC [15]. Multifocal AMLs in patients with TSC when
compared to those without TSC are more often large and symp-
tomatic, and AMLEC, EpAML and microscopic AMLs with multiple
elements rather than myoid cells alone, are more common in TSC
[26,27]. Although a combination of EpAML, microscopic AMLs and
AMELC was  100% predictive of TSC in one study, only 3 of 16
cases showed these features [27]. Genetic conﬁrmation or satis-
fying the Tuberous Sclerosis Consensus Conference criteria are the
only means to deﬁnitively diagnosis TSC; some cases may never be
identiﬁed.
We stained the spectrum of TSC renal lesions for hamartin and
tuberin to determine if the staining proﬁle could serve as a sur-
rogate marker for the TSC1 or TSC2 mutation present, or imply the
presence of TSC in a patient with multiple AMLs without extrarenal
stigmata. Although we lack genetic data, in a series of 14 TSC
patients a couple of TSC1 mutations could be present, although,
most would likely be TSC2. We found that hamartin and tuberin
expression of control kidneys was identical to the staining pattern
of TSC and possible TSC cases. Although only a single functional
allele of one TSC gene was  present, no difference in staining inten-
sity of normal nephrons between TSC and controls was identiﬁed
to suggest the underlying mutation.
We  found that the cellular localization of hamartin and tuberin
in normal tissues differed. Hamartin demonstrated a luminal brush
border-like reaction in PT, and an apical and peripheral cell mem-
brane reaction in DT/CD. The apical and peripheral staining patterns
may  reﬂect hamartin’s interaction with the ezrin-radixin-moesin
family of activating proteins involved in cell adhesion [28]. In con-
trast, tuberin demonstrated a cytoplasmic reaction consistent with
its localization in the Golgi apparatus and its role in regulation of
cytoplasmic vesicle transport to the cell membrane [28]. Autopsy
studies of TSC and non-TSC patients have found that renal tubules
stain for both proteins but differed from our results showing distal
tubule accentuation for both without a brush border-like luminal
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Fig. 5. (A) Eosinophilic microcyst. This is an eosinophilic microcyst in a TSC patient.
(B) Eosinophilic microcyst. The eosinophilic microcyst in (A) is stained for hamartin.
Note the brush border staining reaction of equal intensity as the adjacent normal
proximal tubules. Immunoperoxidase stain for hamartin. (C) Eosinophilic microcyst.









Fig. 6. (A) Angiomyolipoma. The macroscopic myoid cell predominant angiomy-
olipoma at the top shows diffuse intense hamartin staining. The cortex below
serves as a positive internal control. Immunoperoxidase stain for hamartin. (B)
this postulate appears to be invalid in our cases.taining reaction of equal intensity as the adjacent normal tubules. Immunoperox-
dase stain for tuberin.
taining of PT for hamartin [29,30]. Post mortem autolysis affecting
ntigenicity may  explain this difference.
The PT brush border-like staining of EC and EMC  with hamartin
upport PT derivation. This ﬁts with the histology of EMC  that
esembles PT and their characteristic location in the cortical
abyrinth predominately populated by PT. One might predict that
he functionality of hamartin or tuberin would be affected in theAngiomyolipoma. This ﬁeld is comparable to (A). It shows no tuberin staining of
the  macroscopic angiomyolipoma on the top. The cortex below serves as a positive
internal control. Immunoperoxidase stain for tuberin.
cyst epithelium depending upon the mutation due to a second hit
to the normal allele. However, the protein expression with the anti-
bodies employed, appeared unaltered. Although haploinsufﬁciency
for TSC1 and TSC2 has been shown to be sufﬁcient for cyst formation
in rat (Eker) and mouse models of renal cyst formation, mutation
of the normal allele in TSC may  not be required for cyst formation
in humans. The positive staining may  represent wide-type protein
[31,32].
We unexpectedly found reciprocal expression of hamartin and
tuberin between AMLs and RCCs, but similar staining within the
types of RCCs. Hamartin was  ubiquitously expressed in AMLs from
TSC, possible-TSC cases and sporadic non-TSC cases. Conversely,
tuberin was negative in all AMLs except 1 our only EpAML, of note
since tuberin expression is a feature of epithelial differentiation in
RCCs. Plank, et al. in their IH study of multiple AMLs in two TSC
patients reported hamartin negative/tuberin positive AML  stain-
ing in a TSC1 patient and hamartin positive/tuberin negative AML
staining in a TSC2 patient, suggesting that loss of IH staining corre-
lated with the gene mutation [33]. By extrapolation, these ﬁndings
could imply the presence of a TSC2 mutation in our TSC patients
with AMLs. However, since we had 5 patients with hamartin pos-
itive/tuberin negative AMLs who  had concurrent tuberin positive
RCCs that showed no (3 cases) or weak hamartin staining (2 cases),The expression of hamartin or tuberin in TSC neoplasms appears
independent of the underlying mutated gene in a cell differentia-
tion speciﬁc manner. The myoid cells and arteries in AMLs, smooth
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Fig. 7. (A) Renal cell carcinoma. This eosinophilic-cystic renal cell carcinoma is pos-
itive for tuberin while its supporting capillaries are negative. Immunoperoxidase
stain for tuberin. (B) Renal cell carcinoma. This eosinophilic-cystic renal cell car-
cinoma is negative for hamartin although its supporting capillaries are positive.

























Fig. 8. (A) Angiomyolipoma and renal cell carcinoma. This shows an angiomy-
olipoma at the top and an adjacent eosinophilic-cystic renal cell carcinoma at the
bottom. Immunoperoxidase stain for Hamartin. (B) Angiomyolipoma and renal cell
carcinoma. This ﬁeld comparable to that in (A) shows a portion of an angiomy-
olipoma at the top positive for hamartin. The renal cell carcinoma on the bottom
is  negative although a few inﬂammatory cells and the supporting capillaries are
positive. Immunoperoxidase stain for hamartin. (C) Angiomyolipoma and renal cell
carcinoma. This ﬁeld is comparable to (A). It shows a portion of an angiomyolipoma
sclerosis complex renal disease, Pediatr. Nephrol. 26 (2011) 839–852.
[2] H. Northrup, M.K. Koenig, K.-S. Au, Tuberous sclerosis complex, GeneReviews,
[Internet] Seattle (WA), University of Washington, 1993-2014.uscle in RAT tumors and supporting vasculature in RCCs solely
xpress hamartin, while tuberin is strongly expressed in RCCs in
SC patients, in 5 of 6CC-RCC cases and in 1 EpAML. This suggests
n imbalance in expression may  affect cellular differentiation in
SC tumorogenesis, consistent with reports showing participation
f TSC-complex and mTORC1 in epithelial-mesenchymal and/or
esenchymal-epithelial transformation [34,35].
The lack of information about the mutation status of our
ases represents the major limitation of this study. Knowledge of
he speciﬁc TSC mutation(s) would enable additional assessment
f downstream effects on protein expression and TSC-complex
nteraction. This could provide an explanation for the discordant
xpression of hamartin and tuberin observed in renal mesenchymal
nd epithelial neoplasms and their relationship to cellular differ-
ntiation.
In summary, we show that the IH staining proﬁle for hamartin
nd tuberin in the normal kidney and EC and EMC  of TSC patients
s the same as controls despite the presence of only a single func-
ional allele. The identical staining pattern of the TSC eosinophilic
pithelium to PT implicates PT as the origin of the eosinophilic cysts.
espite the presumed presence of bi-allelic mutations in the renal
umors, the expression of hamartin and tuberin in our series of
MLs and RCCs are cell-type speciﬁc. Finally, the reciprocal stain-
ng proﬁle of AML and RCCs in TSC and non-TSC does not permit
mplication of mutation status, nor allow determination if a patient
ith multifocal AML  has TSC.at  the top negative for tuberin. The renal cell carcinoma on the bottom is positive
while the supporting capillaries are negative. Immunoperoxidase stain for tuberin.
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